Jim Cramer's Top Stock Picks For 2022: Going For The Tried, Tested and True

Honeywell (HON)

“At this point in the business cycle, the playbook says you have to go with more tangible companies that make real things and generate real profits,” Cramer said last week on CNBC.

One company he feels fits that bill is Fortune 100 mainstay Honeywell. (The company was ranked 94 in 2021.)

As a global industrial conglomerate, Honeywell provides an attractively diversified mix of services and products that range from aerospace and building technologies to safety and productivity solutions.

Despite a snarled global supply chain and decreased demand from its deep-pocketed airline customers, Q3 2021 saw Honeywell increase sales by 8% year over year. Earnings per share increased by 29% over the same period.

Industry-leading tools, tailored to your level of investment experience

Sponsored

With Qtrade Direct Investing™, you can build, evaluate and test your portfolio using analyst research and tools that feature their most advanced risk analysis and portfolio-building technology.

Now get up to $150 sign-up bonus until June 30, 2023 with promo code BONUS150.

Division of Credential Qtrade Securities Inc.

Get Started

Bausch Health Companies (BHC)

Bausch Health is a Canadian pharmaceutical company that develops, manufactures and markets pharma products and branded generic drugs that target a wide variety of health disorders.

Pharma and healthcare companies are always intriguing plays during times of high inflation, as their products remain in demand even if prices rise. The same is true of farmland.

Cramer, however, is most excited by the fact that Bausch plans on breaking itself into three separate entities: eye health, medical aesthetics and pharmaceuticals.

“I like a big breakup story,” he said during a recent episode of Halftime Report. “Among planned splits at Johnson & Johnson, General Electric and Bausch, I like Bausch Health as the best breakup.”

Bausch’s stock has risen just under 15% in the past 12 months.

Chevron (CVX)

Chevron is looking pretty good.

America’s second largest oil company continues to benefit from the ongoing inflation-driven rally in energy prices. But it also plans on investing a gargantuan sum of money into its renewable natural gas and hydrogen businesses — US$10 billion by 2028 — that should keep the company relevant for decades to come.

Chevron had an expectation-topping Q3 last year: US$6.1 billion in earnings, US$5.6 billion in debt reduction and US$2.6 billion in dividends paid out to investors.

The company’s stock is up over 30% in just the last four months. It could go even higher.

“I like Chevron because I just think that oil is still undervalued even after last year,” Cramer said.

Commission-free trading

Sponsored

Don't let your portfolio get dragged down by commission fees. Wealthsimple Trade lets you trade for $0 commission, and for a limited time, you can get two free stocks for signing up and funding your account. Will you get Apple stock? How about Air Canada?

Get your free stocks

Eli Lilly (LLY)

Pharma giant Eli Lilly expects the sale of COVID antibody-based treatments to help it make a projected US$28 billion in sales for 2021, but the company is also making progress with its experimental Alzheimer’s drug, donanemab.

In June, the Food and Drug Administration designated donanemab a “breakthrough therapy” based on preliminary clinical evidence. That means the FDA will expedite the drug’s review. A decision regarding the drug’s approval is expected in the second half of 2022.

A bet on Eli Lilly isn’t simply a speculative play based on new drugs. The company’s stock is up more than 215% over the last five years — a very lucrative pickup in recent years, especially if you had invested using no-commission investment apps.

More from MoneyWise

• Rick Rule: Your Cash Savings Will Be Crucial During a 'Dramatic Reckoning'
• Meet the Millennials Who Are Turning Their Houseplants Into Investments
• With Interest Rates About to Rise, Here Are the Debts to Pay Off First